Tag: purchase

Q2 2025 revenues increased ~76% to $23.7 million and gross profit increased ~182% to $6.3 million

8.3

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenbacker, an energy transition-focused investment manager and independent power producer, today announced the sale of a 51.2 MW portfolio of 64 operating solar assets to CleanCapital, a leading independent power producer specializing in distributed clean energy. This transaction reflects Greenbacker’s broader strategy to optimize its project fleet for long-term growth with selective sales of non-core assets and a sharpened focus on larger-scale clean energy projects. The sale also supports greater operational efficiency, allowing the firm to reallocate resources toward the construction of higher-impact projects across its pre-operating portfolio.

Management to Hold Call Following Market Close Today

FORM 8.3

Research shows growing affordability crisis in France’s largest cities, with mid-sized towns offering better value.

Pratteln, Switzerland, 13 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion of AGAMREE® (vamorolone) in Türkiye for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2.9999 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Compass are expected to be approximately $120 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about August 14, 2025, subject to customary closing conditions. In addition, Compass has granted the underwriters a 30-day option to purchase up to 6,000,000 additional shares of common stock at the public offering price, less the underwriting discount.